Drugs / ABBV-668
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06477926 | Jul → Sep 2024 | — | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05570006 | Mar 2023 → Dec 2024 | ulcerative colitis | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06477926 ↗ |
| Route | Oral | “Participants will receive oral capsules of ABBV-668 twice daily for 16 weeks” NCT05570006 ↗ |